优化稳定性冠心病PCI试验设计:JACC前沿综述
该综述探讨稳定性冠心病经皮冠状动脉介入(PCI)试验设计中的挑战,包括终点选择、入选人群、背景药物治疗及安慰剂对照的适用性;强调多利益相关方参与以确保设计方法学有效且临床有意义。
要点
- PCI试验设计需明确医生与患者共同关心的终点。
- 入选人群与背景药物治疗是试验设计的关键考量。
- 多利益相关方参与可提升试验设计的临床意义。
核心结论
- 未来PCI试验应让患者、研究者、监管者和资助者等多方参与,确保设计方法学有效且临床有意义。
研究设计与样本
- 本文为JACC前沿综述,讨论稳定性冠心病PCI试验设计面临的挑战及可能选项的利弊。
主要发现
- 综述指出残留不确定性源于终点选择、入选人群、背景药物治疗和安慰剂对照相关性等设计挑战。
临床怎么用
- 设计未来PCI试验时需综合考量终点、人群、背景治疗和对照设置,并纳入多方利益相关者意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.
引用
- Marquis-Gravel G, Moliterno DJ, Francis DP, et al. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020. PMID: 32703515. doi:10.1016/j.jacc.2020.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。